Treatment with pirtobrutinib achieved an ORR of 62%, similar to CLL patients with covalent BTK inhibitor resistance and represents a promising alternative therapy choice to covalent inhibitors [101]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.